Storia in 6 fonti

Replimune secures FDA approval for melanoma therapy Tudriqev after long regulatory battle

In a remarkable turnaround, Replimune has reversed the fortune of its melanoma therapy, winning FDA approval after two prior rejections and agency leadership shakeups. | In a remarkable turnaround, Replimune has reversed the fortune of its melanoma therapy, winning FDA approval after two prior rejections and agency leadership shakeups.

Raccontata da

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

fiercepharma.comStai leggendo4 g fa

Replimune secures FDA approval for melanoma therapy Tudriqev after long regulatory battle

originale

Timeline cronologica

giovedì 6 agosto 2026·biopharmadive.com
Replimune rebounds to win FDA approval of melanoma drug
The accelerated clearance follows two earlier rejections and the support of an advisory panel that disputed the arguments of FDA scientists.
giovedì 6 agosto 2026·statnews.com
FDA approves Replimune melanoma drug previously rejected twice
The FDA approved Replimune’s treatment for advanced melanoma, dealing the company and patient advocates a big win after a tumultuous saga.

Replimune secures FDA approval for melanoma therapy Tudriqev after long regulatory battle

Confronto fonti

Replimune secures FDA approval for melanoma therapy Tudriqev after long regulatory battle

Timeline cronologica

Replimune rebounds to win FDA approval of melanoma drug

FDA approves Replimune melanoma drug previously rejected twice

Replimune rebounds to win FDA approval of melanoma drug

FDA approves Replimune melanoma drug previously rejected twice

Replimune melanoma drug snags coveted FDA approval after yearlong clash, two rejections

FDA approves Replimune's Tudriqev melanoma drug on third try

FDA OKs accelerated approval to twice-rejected Tudriqev with Opdivo for advanced melanoma

Replimune melanoma drug snags coveted FDA approval after yearlong clash, two rejections

Replimune secures FDA approval for melanoma therapy Tudriqev after long regulatory battle

FDA OKs accelerated approval to twice-rejected Tudriqev with Opdivo for advanced melanoma

FDA approves Replimune's Tudriqev melanoma drug on third try